01:46 , Dec 2, 2015 |  BC Extra  |  Financial News

Velicept raises first tranche of $21M series B

Velicept Therapeutics Inc. (Malvern, Pa.) raised an undisclosed first tranche of a planned $21 million series B round of funding led by CAM Capital and Longitude Capital. Velicept intends to begin a Phase II study...
07:00 , Jul 27, 2015 |  BC Week In Review  |  Company News

AltheRx, Velicept deal

Velicept will merge with AltheRx, and the surviving company will retain Velicept’s name and focus on the development of solabegron . The adrenergic receptor beta 3 ( ADRB3 ) agonist has completed Phase II testing...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

AltheRx board of directors update

AltheRx Pharmaceuticals , Exton, Pa.   Business: Autoimmune, Genitourinary   Appointed: Charles Becker, chairman of Becker Ventures, as chairman; Jeffery O'Donnell, a managing director of BioStar Ventures, as vice chairman; and Anthony Zook, formerly CEO...
07:00 , May 6, 2013 |  BC Week In Review  |  Financial News

AltheRx completes venture financing

AltheRx Pharmaceuticals , Exton, Pa.   Business: Autoimmune, Genitourinary   Date completed: 5/2/13   Type: Venture financing   Raised: $15 million   Investors: Becker Ventures; and other undisclosed investors  ...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

AltheRx management update

AltheRx Pharmaceuticals , Exton, Pa.   Business: Autoimmune, Genitourinary   Hired: Jim Bennethum, an EVP at Becker Ventures, as CEO and a director; he succeeds Shawn O'Brien, who departed  ...
00:23 , May 3, 2013 |  BC Extra  |  Financial News

AltheRx raises $15M, names new CEO

AltheRx Pharmaceuticals (Exton, Pa.) raised $15 million in a series A round led by existing investor Becker Ventures. Becker's Jim Bennethum also took over as CEO and became a director, replacing Shawn O'Brien, who departed....
08:00 , Mar 5, 2012 |  BC Week In Review  |  Clinical News

Solabegron: Phase II data

A double-blind, international Phase II trial in 258 women with moderate to severe OAB symptoms showed that twice-daily 125 mg solabegron met the primary endpoint of reducing the mean number of incontinence episodes per 24...
01:54 , Mar 2, 2012 |  BC Extra  |  Clinical News

AltheRx's solabegron meets overactive bladder endpoint

AltheRx Pharmaceuticals Inc. (Malvern, Pa.) said solabegron met the primary endpoint of reducing the mean number of incontinence episodes per 24 hours from baseline to week eight vs. placebo in a Phase II trial to...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Company News

AltheRx Pharmaceuticals Inc., GlaxoSmithKline deal

AltheRx acquired solabegron ( GW427353 ) from GlaxoSmithKline for an undisclosed sum. AltheRx plans to begin Phase III testing of the adrenergic receptor beta 3 agonist ( ADRB3 ) for overactive bladder (OAB) by year...
23:59 , Mar 24, 2011 |  BC Extra  |  Company News

AltheRx acquires Solabegron from GSK

AltheRx Pharmaceuticals Inc. (Chadds Ford, Pa.) acquired Solabegron ( GW427353 ) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for an undisclosed amount. AltheRx plans to begin Phase III testing of the adrenergic receptor beta 3 agonist (...